Dr. Kelly Mcnagny

Biography

Kelly McNagny obtained a BSc in Biology and Biotechnology from Worcester Polytechnic Institute (WPI) in Massachusetts and subsequently earned a PhD in Cellular Immunology from the University of Alabama at Birmingham (UAB). At UAB, she worked with Dr. Max D. Cooper, a founding father of B cell immunology, focusing her research on how cell surface proteins regulate B cell maturation and homing. She then moved to the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, for her postdoctoral studies with Dr. Thomas Graf, where her work concentrated on the transcriptional control of stem cell fate commitment and the development of macrophages, eosinophils, and thrombocytes. At the Biomedical Research Centre at the University of British Columbia in Vancouver, she identified several novel hematopoietic stem cell surface proteins (the CD34 family), which became the focus of her own laboratory. Currently, she is a full professor in the departments of Biomedical Engineering and Medical Genetics, with research that emphasizes stem cell behavior, innate immune responses, inflammatory disease, cancer biology, and immunotherapeutics. Her research heavily relies on the use of transgenic mice and animal models of human inflammatory disease, alongside high-throughput “omics” technologies to reveal immune components that determine human disease outcomes. She has served in leadership roles at the Stem Cell Network Centre of Excellence and the AllerGen Network Centre of Excellence, and is currently a Co-leader of the Immunotherapeutics Cluster at UBC and a delegate for CIHR.

Research Interests

Experience